Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Swan GE, Jack LM, Javitz HS, McAfee T, McClure JB.

CNS Drugs. 2008;22(3):239-56.

PMID:
18278978
2.

Heterogeneity in 12-month outcome among female and male smokers.

Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T.

Addiction. 2004 Feb;99(2):237-50.

PMID:
14756716
3.

Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective.

Javitz HS, Swan GE, Zbikowski SM, Curry SJ, McAfee TA, Decker DL, Patterson R, Jack LM.

Am J Manag Care. 2004 Mar;10(3):217-26.

4.

Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome.

Swan GE, Jack LM, Curry S, Chorost M, Javitz H, McAfee T, Dacey S.

Nicotine Tob Res. 2003 Dec;5(6):911-21.

PMID:
14668075
5.

Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.

Chengappa KN, Kambhampati RK, Perkins K, Nigam R, Anderson T, Brar JS, Vemulapalli HK, Atzert R, Key P, Kang JS, Levine J.

J Clin Psychiatry. 2001 Jul;62(7):503-8.

PMID:
11488359
6.

Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G.

Addiction. 2004 Sep;99(9):1206-18.

PMID:
15317642
7.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
8.

Psychological mediators of bupropion sustained-release treatment for smoking cessation.

McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB.

Addiction. 2008 Sep;103(9):1521-33. doi: 10.1111/j.1360-0443.2008.02275.x.

9.

Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective.

Javitz HS, Swan GE, Zbikowski SM, Curry SJ, McAfee TA, Decker D, Patterson R, Jack LM.

Value Health. 2004 Sep-Oct;7(5):535-43.

10.

Smoking cessation intervention in parents of young children: a randomised controlled trial.

Abdullah AS, Mak YW, Loke AY, Lam TH.

Addiction. 2005 Nov;100(11):1731-40.

PMID:
16277633
11.

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.

Clin Ther. 2001 May;23(5):744-52.

PMID:
11394732
12.

Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS.

JAMA. 2002 Jul 24-31;288(4):468-74.

PMID:
12132977
13.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group..

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
14.

Smoking cessation treatment in a real-life setting: the Greek experience.

Rovina N, Nikoloutsou I, Dima E, Michailidou M, Roussos C, Gratziou C.

Ther Adv Respir Dis. 2007 Dec;1(2):93-104. doi: 10.1177/1753465807085799.

PMID:
19124351
15.

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.

Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J.

Nicotine Tob Res. 2001 May;3(2):131-40.

PMID:
11403727
16.

The English smoking treatment services: one-year outcomes.

Ferguson J, Bauld L, Chesterman J, Judge K.

Addiction. 2005 Apr;100 Suppl 2:59-69.

PMID:
15755262
17.

Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: a naturalistic, open-label study.

Karam-Hage M, Robinson JD, Lodhi A, Brower KJ.

Curr Clin Pharmacol. 2014 May;9(2):123-9.

18.

Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.

Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, Dozier G, Bars MP, Jamerson BD.

Am J Med. 2004 Feb 1;116(3):151-7.

PMID:
14749158
19.

Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.

Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, Bergman K.

Arch Intern Med. 2003 Oct 27;163(19):2337-44.

PMID:
14581254
20.

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD.

Ann Intern Med. 2001 Sep 18;135(6):423-33.

PMID:
11560455
Items per page

Supplemental Content

Support Center